Published : Dec-2020
No. of Pages : 228
1.1 List of Tables
1.2 List of Figures
2 Rheumatoid Arthritis: Executive Summary
2.1 Biosimilar and Generic Erosion Will Stymie Sales Growth in the RA Market from 2019-2029
2.2 Development of Novel Oral Agents and Biosimilars Are Popular R&D Strategies
2.3 Opportunities Remain for More Rapid, Targeted, and Cost-Effective Treatment for RA Patients
2.4 Late-Stage RA Pipeline Holds Promise But Likely Won't Match the Utility of JAK Inhibitors
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology
4.2 Pathophysiology
4.3 Symptoms and Severity Classifications
5 Epidemiology
5.1 Risk Factors and Comorbidities
5.2 Global and Historical Trends
5.3 Forecast Methodology
5.4 Epidemiological Forecast for RA (2019-2029)
5.5 Discussion
6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 US
6.3 5EU
6.4 Japan
6.5 Australia
7 Competitive Assessment
7.1 Overview
7.2 Biosimilars in the RA Market
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Earlier Diagnosis and Treatment
8.3 Cost-Effective Therapies
8.4 Personalized Treatment Strategies
8.5 Improved Guidance on Treating RA Patients in Remission
8.6 New Treatment Options for Patients with Refractory RA
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.3 Other Drugs in Development - Kinase Inhibitors
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Portfolio Assessments
11 Market Outlook
11.1 Global Markets
11.2 US
11.3 5EU
11.4 Japan
11.5 Australia
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.4 Primary Research - KOLs and Payers Interviewed for This Report
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.7 About GlobalData
12.8 Contact Us
12.9 Disclaimer
List of Tables
Table 1: RA: Key Metrics in the 8MM
Table 2: RA Disease Severity Classification
Table 3: Risk Factors and Comorbidities for RA
Table 4: Classification Criteria for RA - ACR 1987
Table 5: Classification Criteria for RA - ACR/EULAR 2010
Table 6: Treatment Guidelines for RA, 2020
Table 7: ACR/EULAR Diagnostic Definitions of Remission in RA Clinical Trials
Table 8: Country Profile - US
Table 9: Regional Profile - 5EU
Table 10: Country Profile - Japan
Table 11: Country Profile - Australia
Table 12: Leading Branded Treatments for RA, 2020
Table 13: Marketed Biosimilars for RA, 2020
Table 14: Expected Adalimumab Biosimilar Launches in the US
Table 15: Pipeline Biosimilars for RA, 2020
Table 16: Average Percent Discount on Biosimilars Compared to Biologic Reference Products Across the 8MM, 2020
Table 17: AbbVie's RA Portfolio Assessment, 2020
Table 18: Pfizer's RA Portfolio Assessment, 2020
Table 19: Amgen's RA Portfolio Assessment, 2020
Table 20: J&J's RA Portfolio Assessment, 2020
Table 21: BMS' RA Portfolio Assessment, 2020
Table 22: Roche/Genentech's RA Portfolio Assessment, 2020
Table 23: Eli Lilly's RA Portfolio Assessment, 2020
Table 24: UCB's RA Portfolio Assessment, 2020
Table 25: Sanofi's RA Portfolio Assessment, 2020
Table 26: Regeneron's RA Portfolio Assessment, 2020
Table 27: Astellas' RA Portfolio Assessment, 2020
Table 28: Gilead's RA Portfolio Assessment, 2020
Table 29: Galapagos' RA Portfolio Assessment, 2020
Table 30: GSK's RA Portfolio Assessment, 2020
Table 31: R-Pharm's RA Portfolio Assessment, 2020
Table 32: Taisho's RA Portfolio Assessment, 2020
Table 33: RA Market - Global Drivers and Barriers, 2019-2029
Table 34: Key Events Impacting Sales for RA in the US, 2019-2029
Table 35: RA Market - Drivers and Barriers in the US, 2019-2029
Table 36: Key Events Impacting Sales for RA in the 5EU, 2019-2029
Table 37: RA Market - Drivers and Barriers in the 5EU, 2019-2029
Table 38: Key Events Impacting Sales for RA in Japan, 2019-2029
Table 39: RA Market - Global Drivers and Barriers in Japan, 2019-2029
Table 40: Key Events Impacting Sales for RA in Australia, 2019-2029
Table 41: RA Market - Global Drivers and Barriers in Australia, 2019-2029
Table 42: Key Historical and Projected Launch Dates for RA
Table 43: Key Historical and Projected Patent/Exclusivity Expiry Dates for RA
Table 44: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for RA in 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in RA During the Forecast Period, 2019-2029
Figure 3: Competitive Assessment of Recently Approved and Late-Stage Pipeline Agents for the Treatment of RA During the Forecast Period, 2019-2029
Figure 4: Overview of RA Pathogenesis and Pathophysiology
Figure 5: Cellular and Cytokine Targets for the Marketed and Late-Stage Pipeline RA Drugs, 2020
Figure 6: 8MM, Diagnosed Incidence of RA (Cases per 100,000 Population), Both Sexes, Ages ?18 Years, 2019
Figure 7: 8MM, Diagnosed Prevalence (%) of RA, Both Sexes, Ages ?18 Years, 2019
Figure 8: 8MM, Total Prevalence (%) of RA, Both Sexes, Ages ?18 Years, 2019
Figure 9: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of RA
Figure 10: 8MM, Sources Used and Not Used to Forecast the Diagnosed and Total Prevalent Cases of RA
Figure 11: 8MM, Diagnosed Incident Cases of RA, N, Both Sexes, Ages ?18 Years, 2019
Figure 12: 8MM, Diagnosed Incident Cases of RA, N, by Sex, Ages ?18 Years, 2019
Figure 13: 8MM, Diagnosed Incident Cases of RA by Age, N, Both Sexes, 2019
Figure 14: 8MM, Diagnosed Prevalent Cases of RA, N, Both Sexes, Ages ?18 Years, 2019
Figure 15: 8MM, Diagnosed Prevalent Cases of RA, N, by Sex, Ages ?18 Years, 2019
Figure 16: 8MM, Diagnosed Prevalent Cases of RA by Age, N, Both Sexes, 2019
Figure 17: 8MM, Diagnosed Prevalent Cases of RA by Severity, N, Both Sexes, Ages ?18 Years, 2019
Figure 18: 8MM, Total Prevalent Cases of RA, N, Both Sexes, Ages ?18 Years, 2019
Figure 19: 8MM, Total Prevalent Cases of RA, N, by Sex, Ages ?18 Years, 2019
Figure 20: 8MM, Total Prevalent Cases of RA by Age, N, Both Sexes, 2019
Figure 21: 8MM, Total Prevalent Cases of RA by Severity, N, Both Sexes, Ages ?18 Years, 2019
Figure 22: General Treatment Algorithm for RA Patients, 2020
Figure 23: 8MM Physician-Reported Biosimilar Prescription Rates to RA Patients, 2020
Figure 24: 5EU Physician-Reported Biosimilar Prescription Rates to RA Patients, 2020
Figure 25: Unmet Needs and Opportunities in RA, 2020
Figure 26: Overview of the Development Pipeline in RA
Figure 27: Key Phase II/III Trials for the Promising Pipeline Agents That GlobalData Expects to Be Licensed for RA in the 8MM During the Forecast Period, 2019-2029
Figure 28: Competitive Assessment of Recently Approved and Late-Stage Pipeline Agents for the Treatment of RA During the Forecast Period, 2019-2029
Figure 29: Analysis of the Company Portfolio Gap in RA During the Forecast Period, 2019-2029
Figure 30: Global (8MM) Sales Forecast by Country for RA in 2019 and 2029
Figure 31: Global (8MM) Sales Forecast for RA, by Class, in 2019 and 2029
Figure 32: Sales Forecast by Class for RA in the US in 2019 and 2029
Figure 33: Sales Forecast by Class for RA in the 5EU in 2019 and 2029
Figure 34: Sales Forecast by Class for RA in Japan in 2019 and 2029
Figure 35: Sales Forecast by Class for RA in Australia in 2019 and 2029
